SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung Cancer
(STICk-IM-NSCLC Trial)

Recruiting in Palo Alto (17 mi)

Overseen byScott Floyd, MD PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Duke University

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is studying how the timing of precise brain radiation and immune-boosting therapy affects patients with lung cancer that has spread to the brain.

Research Team

Jeffrey Clarke, MD

Principal Investigator

Duke Health

Scott Floyd, MD PhD

Principal Investigator

Duke Health

Eligibility Criteria

Inclusion Criteria

Squamous NSCLC

Adenocarcinoma NSCLC

Not otherwise specified NSCLC

See 7 more

Treatment Details

Interventions

Immune Checkpoint Inhibition (Checkpoint Inhibitor)
Stereotactic Radiosurgery (Radiation)

Participant Groups

2Treatment groups

Experimental Treatment

Group I: Immediate SRS followed by IOExperimental Treatment2 Interventions

Participants will receive SRS followed by physician's choice of standard of care immunotherapy, given at the FDA-approved dose within 14 days of SRS.

Group II: Immediate IO followed by SRSExperimental Treatment2 Interventions

Participants will receive physician's choice of immunotherapy, given at the FDA-approved dose followed by SRS, if deemed appropriate, at the time of intracranial progression.